“Characteristics and outcomes of 627,044 COVID-19 patients with and without obesity in the United States, Spain, and the United Kingdom,” a new OHDSI study generated by the CHARYBDIS team, is available as a preprint on MedRxiv.
The prevalence of obesity in 627,044 COVID-19 patients was more common than in the 4.5 million influenza patients used in the study, which spanned six databases. Hospitalization, intensive services, and fatality rates were higher within obese COVID-19 patients than non-obese ones.
The prevalence of obesity was higher among hospitalized COVID-19 (range: 38% to 54%) than either diagnosed COVID-19 (30% to 47%) or diagnosed/hospitalized influenza (15% to 48%) patients. Obese hospitalized COVID-19 patients were more often female and younger than non-obese COVID-19 patients or obese influenza patients.
Obese COVID-19 patients were also more likely to have prior comorbidities, present with cardiovascular and respiratory events during hospitalization, require intensive services, or die compared to non-obese COVID-19 patients.
The research team, led by lead authors @mrecalde and Elena Roel, hopes these findings can guide preventative strategies for infection/complications. The research team is seeking feedback on the study, which is currently under the peer-review process.
The CHARYBDIS (Characterizing Health Associated Risks, and Your Baseline Disease In SARS-COV-2) Project is an OHDSI initiative that attempts to describe the baseline demographic, clinical characteristics, treatments and outcomes of interest among individuals tested for SARS-CoV-2 and/or diagnosed with COVID-19 overall and stratified by sex, age and specific comorbidities, as compared to Influenza patients from 2017-2018. More information on CHARYBDIS is available on its GitHub page.
Preprints are preliminary reports of work that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.